Skip to main content
. 2021 May 14;43(3):672–680. doi: 10.1038/s41401-021-00683-8

Fig. 4. The anti-HER2×PD1 BsAb retained ADCC toward tumor cells but not T cells.

Fig. 4

a The BsAb exhibited a potency in lysing tumor cells similar to that of trastuzumab in the ADCC assay. b The BsAb and trastuzumab failed to mediate ADCC toward T cells, whereas an anti-MHC1 IgG1 antibody showed strong potency in lysing T cells in a dose-dependent manner [44].